Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer

Last year a handful of setbacks led shares of Regeneron Pharmaceuticals NASDAQ REGN about 29 lower while Pfizer NYSE PFE stock ended 2016 about 2 higher than it began Sales of Regeneron s lead product have been tapering off but a handful of potential blockbusters